Vijaya Diagnostic Centre Limited announced the outcome of its Board Meeting held on February 13, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December 31, 2025. Furthermore, significant management changes were ratified, including the appointment of a new CFO, CTO, and COO, alongside the addition of two new Non-Executive Independent Directors. The Board also approved the grant of 1,15,000 ESOPs.
Outcome of Board Meeting: February 13, 2026
The Board of Directors of Vijaya Diagnostic Centre Limited convened on Friday, February 13, 2026, to consider and approve several key corporate actions and financial disclosures. The meeting commenced at 12:30 P.M. and concluded at 02:30 P.M. (IST).
Financial Results Noted
The Board inter-alia considered and noted the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and the nine months ended December 31, 2025.
Key Board Approvals and Appointments
New Appointments to the Board
Based on the recommendation of the Nomination and Remuneration Committee, the Board approved the appointment of two additional directors for a period of five (5) years, effective from February 13, 2026, subject to shareholder approval:
- Mr. Ravi Shankararamiah (DIN: 00180746) as a Non-Executive-Independent Director.
- Dr. Sasikala Paruchuri Kola (DIN: 00129614) as a Non-Executive-Independent Director.
Executive Leadership Changes
The Board approved the following key appointments effective from February 13, 2026:
- Appointment of Mr. Ankit Shah as the Chief Financial Officer (CFO) & Key Managerial Personnel. He is also authorized to handle disclosures to stock exchanges.
- Appointment of Mr. Sai Prasad as the Chief Technology Officer (CTO).
- Appointment of Mr. Venkata Siva Rama Raju Vegesna as the Chief Operating Officer (COO).
CFO Resignation Noted
The Board noted the resignation of Mr. S. Ramachandra Reddy from the position of Chief Financial Officer (CFO), effective February 13, 2026. Mr. Reddy will continue to serve the Company as General Manager – Finance & Accounts following organizational restructuring.
Employee Stock Option Plan (ESOP) Grant
The Board approved the Grant of 1,15,000 Employee Stock Options (ESOPs) under the “VDCL Employee Stock Option Plan 2018”. These options, convertible into 1,15,000 equity shares of face value ₹1/- each, are being granted at an exercise price of ₹809/- per option. This exercise price represents the average closing price during the preceding three months, reduced by a 20% discount. The options will commence vesting after a one (1) year period from the grant date.
Policy Revision
Based on the recommendations of the Audit Committee, the Board of Directors has also revised the Policy for dealing in Related Party Transaction (RPT Policy).
Source: BSE
